PDCD1 and non-small cell lung carcinoma: Antibody-mediated blockade of programmed cell death protein-1 (PD-1) or cell-surface localized programmed cell death ligand-1 (PD-L1) provides a novel therapeutic paradigm for patients with advanced NSCLC [2–6].